Form 8-K - Current report:
SEC Accession No. 0001213900-25-053844
Filing Date
2025-06-12
Accepted
2025-06-12 16:17:51
Documents
12
Period of Report
2025-06-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245492-8k_protara.htm   iXBRL 8-K 36098
  Complete submission text file 0001213900-25-053844.txt   202046

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tara-20250611.xsd EX-101.SCH 3017
3 XBRL LABEL FILE tara-20250611_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE tara-20250611_pre.xml EX-101.PRE 22360
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0245492-8k_protara_htm.xml XML 3691
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 251042707
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)